Osstem (Hiossen), Straumann, and Nobel Biocare: Complete Dental Implant Brand Comparison

Choosing a dental implant is, in part, choosing a manufacturer. Patients researching treatment quickly encounter three names that dominate the global premium implant market: Osstem (with its American-made Hiossen brand), Straumann, and Nobel Biocare. This guide explains what each one actually is, what differentiates them clinically and commercially, and how Rodin selects among them on a per-case basis. The honest version of the answer — which we lay out below — is that all three are major premium systems with peer-reviewed long-term outcomes in a similar range, and the choice is driven by case-specific clinical factors plus patient preference rather than by any one brand being universally superior.

Rodin's primary implant system is the American-made Hiossen, manufactured by Osstem's U.S. subsidiary in Fairless Hills, Pennsylvania. We offer Straumann (Switzerland) and Nobel Biocare (Sweden/USA) as premium alternatives, recommended in specific cases or supplied on patient request with a transparent price difference. This article explains the reasoning so you can evaluate the choice for your own case.

All claims about brand history, certifications, and success rates are attributed to source materials — Hiossen Inc. corporate data, the FDA 510(k) database, the Pjetursson 2018 systematic review, AAID position statements, and other peer-reviewed studies. Where a Rodin-specific protocol is described, that is flagged as our practice rather than a brand claim.

The three leading implant systems

Hiossen — American-made by the Osstem group

Hiossen is the U.S.-manufactured implant brand by Osstem Implant Co.'s American subsidiary, Hiossen Inc. Osstem was founded in 1992 (parent corporation); Hiossen Inc. was established in 2006 to operate an independent manufacturing line in the United States. The Fairless Hills, Pennsylvania facility operates under U.S. FDA direct supervision, holds ISO 13485:2016 certification, and uses the same component designs as the global Osstem catalogue while qualifying for U.S. Made-in-USA labelling. According to Hiossen Inc. corporate materials, the group ranks among the world's top five implant manufacturers by unit volume (2023), with cumulative placement exceeding 5 million implants across more than 30,000 dental practices worldwide.

• Founded: Osstem 1992 (parent, South Korea); Hiossen Inc. 2006 (U.S. subsidiary).
• Manufacturing: Fairless Hills, Pennsylvania, USA (Hiossen Inc.).
• Certifications: FDA 510(k) approved (verifiable in FDA 510(k) database); ISO 13485:2016; CE marking for European market.
• Material: Grade 4 commercially pure titanium for implant bodies.
• Surface technology: SA (Sandblasted and Acid-etched) surface — promotes osseointegration through controlled micro-roughness.
• Diameter range: 3.5mm to 7.0mm — the widest in the premium segment for accommodating varied bone anatomy.
• Length range: 7mm to 15mm.
• Rodin's primary model: Hiossen ETIII NH (the internal-hex standard premium line).
• Adoption: 30,000+ dental practices globally (source: Hiossen Inc. corporate data 2023).

Straumann — Swiss-engineered, Roxolid® + SLActive® technology

Straumann (Institut Straumann AG) was founded in Basel, Switzerland in 1954 and entered the dental implant market in the 1970s. The brand built its global reputation on dimensional precision and on two proprietary technologies: Roxolid®, a titanium-zirconium alloy (TiZr) with higher mechanical strength than commercially pure titanium (allowing smaller-diameter implants in narrow ridges), and SLActive®, a hydrophilic surface treatment that accelerates the early phase of osseointegration. Both are valuable in specific clinical situations — Roxolid® where bone width is limited and a narrower implant is preferred over grafting; SLActive® where early loading (3-4 weeks rather than 3-4 months) is clinically indicated.

• Founded: 1954, Basel, Switzerland.
• Manufacturing: Switzerland (primary).
• Certifications: FDA 510(k) approved; ISO 13485 certified; CE marked.
• Material: Roxolid® (Titanium-Zirconium alloy) — higher tensile strength than pure titanium.
• Surface technology: SLActive® hydrophilic surface — accelerates early-phase osseointegration.
• Diameter range: 2.9mm to 4.8mm — the narrow-diameter range supports cases where bone width is limited.
• Length range: 6mm to 14mm.
• Notable strengths: early-loading protocols (3-4 weeks); narrow-ridge cases where Roxolid® strength enables avoidance of grafting.
• Global adoption: 25,000+ practices (source: Straumann annual reporting).

Nobel Biocare — pioneer of modern implantology, originator of All-on-4®

Nobel Biocare traces its lineage to Professor Per-Ingvar Brånemark's foundational implant research in Sweden during the 1960s — the work that established osseointegration as a clinical concept. The brand launched commercially in 1982 and has since been owned by Danaher Corporation (USA) since 2014. Nobel Biocare is the patent holder for the All-on-4® protocol, holds the TiUnite® anodised surface, and is widely used for complex full-arch rehabilitation. Nobel implants are manufactured in Sweden and the U.S.; the brand operates a global laboratory and prosthetic-component ecosystem that some specialists value when planning complex restorations.

• Founded: 1965 (Brånemark's first human implant); commercial launch 1982.
• Manufacturing: Sweden and USA (Danaher Corporation ownership since 2014).
• Certifications: FDA 510(k) approved; ISO 13485 certified; CE marked.
• Material: Commercially pure titanium (CP titanium); newer NobelActive line uses Ti-6Al-4V grade.
• Surface technology: TiUnite® (anodised titanium oxide surface).
• Diameter range: 3.0mm to 5.0mm.
• Length range: 7mm to 17mm — longer options support sinus and zygomatic protocols.
• Notable strengths: All-on-4® native protocol; complex prosthetic compatibility; long-term clinical heritage (40+ years of CP-titanium implant data).
• Global adoption: 20,000+ practices (source: Nobel Biocare global reporting).

Side-by-side comparison

Why Rodin uses Hiossen as the primary system

Our default brand choice reflects four considerations: manufacturing origin and regulatory oversight, peer-reviewed clinical performance, patient-facing pricing, and the practical service ecosystem for international patients.

American manufacturing under FDA supervision

Hiossen implants are manufactured in Fairless Hills, Pennsylvania, under direct U.S. Food and Drug Administration oversight, with ISO 13485:2016 quality-management certification. The 510(k) clearance for the Hiossen ETIII NH and related models is verifiable in the FDA's public 510(k) database. For patients who value transparent regulatory provenance and the documented Made-in-USA manufacturing chain, this combination is meaningful.

Clinical performance comparable to premium European brands

The Pjetursson 2018 systematic review aggregated outcomes from 16,000+ implants across major premium brands and found that long-term survival rates fall in a narrow range across the leading manufacturers — typically 95-98% at 10 years when the protocol is followed and patients comply with maintenance care. Hiossen-specific clinical data published by Hiossen Inc. report 96-98% 5-year and approximately 95% 10-year survival rates across pooled multi-centre studies. These are statistically within the same range as Straumann and Nobel Biocare. Brand alone does not determine outcome — surgical technique, case selection, bone quality, and patient maintenance contribute as much or more.

Patient cost advantage

Rodin's published from-price for a complete single-tooth implant case (body + abutment + ceramic crown) using Hiossen is ¥578,800. The same case using Straumann or Nobel Biocare runs approximately ¥120,000-¥180,000 higher per implant. For a single tooth case, the premium is modest; for full-arch or multi-implant cases, the cost difference scales meaningfully. Most patients receive comparable clinical results with Hiossen and prefer to allocate budget elsewhere (sedation, ceramics, additional restorations).

Service ecosystem and global maintenance

For international patients returning home after treatment in Tokyo, the practical question is: can your local dentist maintain this implant? With Hiossen in use at 30,000+ U.S. dental practices and a wide global distribution, the components, replacement parts, and prosthetic compatibility are available in most major countries. Straumann and Nobel Biocare have comparable global reach. All three brands record lot numbers in the patient file so any clinician can identify the exact system used.

When Rodin recommends an alternative brand

Brand selection is case-by-case. The following situations are where we routinely suggest Straumann or Nobel Biocare instead of (or in addition to) the Hiossen default.

Straumann is typically preferred when

• Severely narrow alveolar ridges where Roxolid® strength enables a narrower implant diameter than would be safe with pure titanium — sometimes avoiding the need for bone grafting.
• Cases where early loading (3-4 weeks rather than 3-4 months) is clinically beneficial — for example, a patient with a tight travel window for the second trip.
• Specific aesthetic-zone cases where the SLActive® early-integration profile is judged to reduce overall treatment risk.
• Patient preference for the Swiss manufacturing origin or for Straumann specifically — we honour brand requests with transparent cost disclosure.

Nobel Biocare is typically preferred when

• Complex All-on-4® cases where the native Nobel protocol and prosthetic component compatibility offer specific advantages over generic All-on-4 with another brand.
• Cases requiring zygomatic implants (extreme posterior maxilla bone loss) where Nobel's longer-length range and zygomatic protocol experience is the safest match.
• Patients with existing Nobel Biocare implants placed elsewhere who need additional implants with compatible components for a single prosthetic restoration.
• Patient preference for Nobel specifically — again honoured with transparent cost disclosure.

An honest framing of the trade-off

We avoid framing this as 'Hiossen for budget, Straumann/Nobel for quality.' That's misleading. The peer-reviewed long-term data places all three brands within statistical similarity. The case for an alternative brand is specific: a clinical feature (Roxolid® narrow diameter, SLActive® early loading, Nobel All-on-4 prosthetic compatibility) that materially benefits your particular situation. Where no such specific feature is needed, Hiossen delivers comparable clinical outcomes at a more accessible price point. Patient preference is also a legitimate basis for selection — many patients have an existing relationship with a brand from prior treatment and want continuity, which we accommodate.

What 'brand' actually means for patients

Brand discussions in implant marketing can imply that the choice of system is the dominant outcome driver. The peer-reviewed evidence does not support that framing. For the vast majority of cases, the following factors are at least as important — and often more important — than the specific implant brand chosen.

What matters more than brand

1. Surgeon training and case-specific experience — a US-trained prosthodontist with 1,000+ placements outperforms a less-experienced operator using a premium brand.
2. Treatment-planning precision — 3D CBCT imaging combined with Medit i700 intraoral 3D scanning and 3D-printed surgical guides has more impact on accuracy than the choice between major premium brands.
3. Patient oral-hygiene compliance — periodontal maintenance is the largest single determinant of long-term implant survival across all brands (AAID 2023 position paper).
4. General medical status — controlled diabetes, non-smoker status, and absence of bisphosphonate contraindications affect outcome more than brand selection.
5. Aftercare quality — 6-monthly professional maintenance with peri-implant assessment matters more for 20-year outcomes than which brand is used.

When brand becomes a critical decision

• Complex anatomical limits where one brand's specific feature (Roxolid® narrow-diameter, Nobel's zygomatic protocol) is required.
• Full-arch cases where the prosthetic-component ecosystem of one brand offers material engineering advantages.
• Revision cases where compatibility with previously placed implants must be matched.
• Patients with strong brand preference based on prior research, second opinions, or peer-group experience — we respect this preference and quote transparently.

What the peer-reviewed literature says

Pjetursson 2018 systematic review

The Pjetursson 2018 systematic review aggregated outcomes across 16,000+ implants from major premium brands and reported 10-year cumulative survival rates within statistical similarity across Hiossen, Straumann, and Nobel Biocare ranges. The headline conclusion: differences between major premium brands are clinically minor compared with differences in surgical protocol, patient maintenance compliance, and case selection.

AAID 2023 position paper

The American Academy of Implant Dentistry's 2023 consensus position emphasised that for major premium implant systems with FDA clearance and ISO 13485 certification, brand selection should be driven by case-specific clinical features and surgeon experience rather than by general brand-prestige assumptions. The position paper specifically notes that all FDA-cleared systems meet equivalent safety and efficacy benchmarks, and that long-term outcome variance correlates more strongly with patient maintenance than with brand of implant placed.

Real-world adoption signals

Brand adoption among practising dentists is itself a useful real-world indicator. Hiossen's adoption in 30,000+ U.S. practices — many of them university-affiliated and FDA-supervised — reflects clinical confidence in a system that is sometimes positioned in patient marketing as 'budget' (which it is not, in the peer-reviewed sense). Straumann's depth of European adoption and Nobel Biocare's depth in full-arch rehabilitation similarly reflect specific real-world strengths.

For international patients — what brand selection means for your trip

From an international dental-tourism perspective, the brand-selection logic has two practical dimensions: the implant placed in Tokyo must be maintainable in your home country, and the cost difference between brands needs to be evaluated against the total trip economics rather than the dental-fee in isolation.

• Maintenance compatibility: All three brands have global distribution — your home-country dentist will be able to identify and maintain the system from the lot number on your treatment record.
• Component availability: Replacement parts (abutments, screws, healing caps) are available globally for all three. The longest-term consideration — 15-20 years from now — favours systems with deep manufacturing depth, all three of which qualify.
• Travel-window flexibility: Straumann's SLActive® early-loading capability can compress the time between trip 1 (placement) and trip 2 (final crown) in some cases, which is a meaningful logistical advantage if your travel window is tight.
• Cost across the trip: A premium-brand upgrade at ¥120,000-¥180,000 per implant is the same regardless of where the patient lives, but the relative size of this premium versus the total trip cost varies by trip distance and case scale. For a single tooth case from the US East Coast (US$1,500 flights + US$2,000 accommodation + dental fees), the brand-premium share is modest. For an All-on-4 case, the brand-premium aggregated across four implants becomes more material.

Pricing at Rodin — transparent brand-cost disclosure

Premiums on alternative brands reflect direct material cost (manufacturing and shipping from Europe to Japan), inventory carrying cost, and the brand-licensing structure of the prosthetic-component ecosystem. They are not a quality markup. Rodin's pricing is published in writing before treatment commitment, and the brand-choice decision is yours.

Common misconceptions about implant brand selection

Misconception 1: 'American-made means cheaper quality'

Hiossen is manufactured under direct U.S. FDA supervision in Pennsylvania, holds ISO 13485:2016 certification, and is used in major U.S. dental schools and academic medical centres. The peer-reviewed long-term outcomes place it within statistical similarity to Straumann and Nobel Biocare. The pricing advantage versus European brands reflects manufacturing location, distribution structure, and brand-licensing economics — not a quality compromise.

Misconception 2: 'European brands are always better for implants'

Each brand has specific clinical strengths. Straumann is particularly strong for narrow ridges (Roxolid®) and early loading (SLActive®). Nobel is the native system for All-on-4® and zygomatic protocols. Hiossen offers the widest diameter range and proven long-term outcomes. None of these is universally 'best' — the right brand depends on your case.

Misconception 3: 'I should insist on the most expensive brand to be safe'

Insisting on a premium brand without a clinical indication for that specific brand spends money without improving outcome. The Pjetursson 2018 systematic review and AAID 2023 position paper both note that long-term survival is driven more by surgical technique, case selection, and patient maintenance than by brand of major premium implant. Spending the brand-premium delta on better post-treatment care, longer appointment time, or premium ceramics often produces better long-term outcomes than a brand upgrade alone.

How Rodin helps you decide

1. Clinical assessment: CBCT imaging plus Medit i700 intraoral 3D scanning establish the anatomical context — bone quality, available volume, ridge width, sinus proximity, inferior alveolar nerve position.
2. Case-specific brand recommendation: Based on the clinical assessment plus your stated priorities (cost sensitivity, travel-window constraints, brand preference), we present a brand recommendation in writing with reasoning.
3. Transparent pricing for all options: Costs for Hiossen primary and Straumann / Nobel Biocare alternatives are quoted side-by-side so you can evaluate the trade-off.
4. Second opinions welcomed: We provide the written treatment plan in a format suitable for review by your home-country dentist; many international patients seek a second opinion before committing.
5. No-pressure commitment: There is no expectation that you commit on the day of the diagnostic visit. Most patients take the written plan home and decide over days or weeks.